Japanese Generic Market Forecast to 2013

According to "Japanese Generic Market Forecast to 2013", a new research report by RNCOS, Japan promises to be one of the most lucrative generic markets in the world. Between 2005 and 2008, the Japanese generics market grew at a CAGR of around 7.5% to register 333 Billion (US$ 3.5 Billion) in revenue.

The Japanese market is characterized by a strong support by the government, which in a desperate bid to limit its healthcare costs, is introducing a number of generic-friendly policies. Other factors such as a large number of patent expiries and the largely un-penetrated nature of the market are also contributing towards the market growth.

The generic market is presently dominated by domestic manufacturers, with the top six manufacturers accounting for 56% of the total market in 2007. But opening up of the market and introduction of a number of generic-friendly reforms is attracting a number of foreign players in the market.

Despite such a big opportunity for future, the market also has a number challenges to deal with. Generic drugs are still regarded as cheap, low quality alternatives of branded drugs. Thus, both physicians and patients are skeptic regarding their safety and efficacy. A number of awareness and educational programs, however, are expected to increase their awareness in future.

Despite these challenges, our forecast models suggest that the generic drugs market will grow at a CAGR of around 8.8% between 2009 and 2013.

The report gives an extensive and objective analysis on the generic market in Japan. It investigates both the past and present trends in the generic market, but its focus is on the future trends shaping the industry. The report also investigates the performance of various players in the Japanese pharmaceutical and generic markets, and analyzes the competitive landscape in these markets. Based on various present and future indicators, the future scenario of the market has also been analyzed.

Key questions answered in the report

• What is the size and penetration level of the Japanese generic market?
• How is the Japanese generic market different from other developed markets?
• What are the key drivers and challenges for the generic market?
• What is the role of government in the market?
• What is the viewpoint of patients and physicians on generic drugs?
• What is the future outlook of the drug market?
• Who are the key players operating in the Japanese generic market?

Key players operating in Japanese generic market

This report features the key players currently operating in the Japanese pharmaceutical and generic markets. This section describes market shares and growth of key pharmaceutical and generic players in Japan. Profiles of the top six generic manufacturers have been provided in the report.

• 1. Analyst View
• 2. The Japanese Pharmaceutical Market
  • 2.1 Country Snapshot
  • 2.2 Market Trend Analysis
  • 2.3 Price Cuts by Government
  • 2.4 Therapy Area Analysis
  • 2.5 Market Share of Key Players
  • 2.6 Market Forecast till 2013
• 3. What is Making Generics So Lucrative in Japan
  • 3.1 Pressure on Government to Cut Skyrocketing Healthcare Costs
  • 3.2 Generic Market is a large Untapped Goldmine
  • 3.3 Margin from Generics is Fairly Higher than Other Developed Markets
  • 3.4 Major Blockbusters Going Off-patent
  • 3.5 Increasing Investment by Major Domestic and Foreign Companies
• 4. The Japanese Generic Market
  • 4.1 Market Trend Analysis
  • 4.2 Generics Substitution has been Slow so Far
  • 4.3 Regulatory Changes and Incentives will Lead to Rapid Adoption in Future
  • 4.4 US and European Generics Strategies will Fail in Japan
  • 4.5 Perception about Generics is a Significant Barrier
  • 4.6 Market Share of Key Players
  • 4.7 Market Forecast till 2013
• 5. Key Players
  • 5.1 Sawai Pharmaceuticals
  • 5.2 Taiyo Pharmaceutical
  • 5.3 Nichi-Iko
  • 5.4 Towa
  • 5.5 Nippon Chemiphar
  • 5.6 Fuji Pharma
• List of Figures:
  • Figure 2-1: Japan - Leading Causes of Death (%), 2005 & 2030
  • Figure 2-2: Japan - Sources of Healthcare Financing (%), 2005
  • Figure 2-3: Japan - Pharmaceutical Market (in Trillion ), FY 2003 to FY 2008
  • Figure 2-4: Japan - NHI Price Cuts in Pharmaceutical Market (%), 1994 to 2008
  • Figure 2-5: Japan - Forecast for Pharmaceutical Market (in Trillion ), FY 2009 to FY 2013
  • Figure 3-1: Japan - Population Aged 65 Years & Above (in Million), 2003-2008
  • Figure 3-2: Japan - Forecast for Population Aged 65 Years & Above (in Million), 2009-2013
  • Figure 3-3: Japan - Healthcare Expenditure and Revenue of NHI (in Trillion ). 2005, 2020 & 2035
  • Figure 3-4: Japan - Share of Generics in Pharmaceutical Market w.r.t Top Seven Markets
  • Figure 3-5: Japan - Cost of Generics w.r.t Other Countries
  • Figure 3-6: Japan - Drug Patent Expiry Cost (in Billion ), 2007 & 2008
  • Figure 4-1: Japan - Generic Market (in Billion ), 2005-2008
  • Figure 4-2: Japan - Generic Market by Manufacturer (%), 2007
  • Figure 4-3: Japan - Forecast for Generic Market (in Billion ), 2009-2013
  • Figure 4-4: Japan - Share of Generics in Pharmaceutical Market (%), 2006 & FY 2012
• List of Tables:
  • Table 2-1: Japan - Key Macroeconomic Indicators (2003-2008)
  • Table 2-2: Japan - Forecast for Key Macroeconomic Indicators (2009-2013)
  • Table 2-3: Japan - Key Demographic and Healthcare Indicators (2003-2008)
  • Table 2-4: Japan - Forecast for Key Demographic and Healthcare Indicators (2009-2013)
  • Table 2-5: Japan - Healthcare Spending Statistics (2003-2008)
  • Table 2-6: Japan - Forecast for Healthcare Spending Statistics (2009-2013)
  • Table 2-7: Japan - Sources of Pharmaceutical Purchases (in Billion ), FY 2007
  • Table 2-8: Japan - Statistics of Top 10 Therapy Areas (FY 2007)
  • Table 2-9: Japan - Statistics of Top 20 Pharmaceutical Players (2007)
  • Table 2-10: Japan - Key Driving and Restraining Factors in Pharmaceutical Market
  • Table 4-1: Japan - Extent of Awareness, Consideration, Request and Prescription in Generic Market (2006)
  • Table 4-2: Japan - Key Driving and Restraining Factors in Generic Market